SCHEMBL13381647

SCHEMBL13381647

COc1ccc(C(N)Cc2cnc[nH]2)cc1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 2/20 0.62
CYP1A2 P05177 2/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2C19 P33261 1/20 0.55
HRH3 Q9Y5N1 6/20 0.54
HRH4 Q9H3N8 4/20 0.53
ALDH1A1 P00352 2/20 0.53
MEN1 O00255 1/20 0.53
GLA P06280 1/20 0.53
KMT2A Q03164 1/20 0.53
NFKB1 P19838 1/20 0.53
THPO P40225 1/20 0.53
TAAR1 Q96RJ0 1/20 0.52
LMNA P02545 1/20 0.51
APEX1 P27695 1/20 0.51
BLM P54132 1/20 0.51
SCN10A Q9Y5Y9 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL631901 0.83 TAAR1 (0.53) CYP19A1CYP1A2HRH3HRH4ALDH1A1
SCHEMBL632088 0.80 NLN (0.61) CYP19A1CYP1A2HRH3HRH4ALDH1A1
SCHEMBL16673386 0.79 ITGB2 (0.51) CYP19A1CYP1A2CYP2C19ALDH1A1
SCHEMBL632220 0.79 HRH4 (0.46) CYP19A1CYP1A2HRH3HRH4ALDH1A1
SCHEMBL27986334 0.73 HRH3 (0.62) CYP19A1HRH3HRH4TAAR1
SCHEMBL21794926 0.72 NLN (0.68)
SCHEMBL12706131 0.72 CYP1A2 (1.00) CYP1A2CYP2D6CYP2C19ALDH1A1TAAR1
SCHEMBL9564556 0.72 CYP1A2 (1.00) CYP1A2CYP2D6CYP2C19ALDH1A1TAAR1
SCHEMBL3164735 0.71 CYP1A2 (0.55) CYP19A1CYP1A2CYP2D6CYP2C19ALDH1A1
SCHEMBL632492 0.70 NLN (0.42) CYP19A1CYP1A2HRH3HRH4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190201414-A1 INHIBITOR OF HEME DEGRADATION FOR USE TO IMPROVE ANTIBIOTIC TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTION THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) 2019-07-04 US disclosed
US-8450368-B2 Heme oxygenase inhibitors, screening methods for heme oxygenase inhibitors and methods of use of heme oxygenase inhibitors for antimicrobial therapy UNIVERSITY OF MARYLAND, BALTIMORE (US) 2013-05-28 US disclosed
US-8450368-B2 Heme oxygenase inhibitors, screening methods for heme oxygenase inhibitors and methods of use of heme oxygenase inhibitors for antimicrobial therapy UNIVERSITY OF MARYLAND, BALTIMORE (US) 2013-05-28 US disclosed
US-20100081661-A1 HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY UNIVERSITY OF MARYLAND, BALTIMORE (US) 2010-04-01 US disclosed
US-20100081661-A1 HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY UNIVERSITY OF MARYLAND, BALTIMORE (US) 2010-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081661-A1 HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY HMOX1, HMOX2, PPOX CYP19A1 1311/4885CYP1A2 85/4885CYP2D6 175/4885
US-20190201414-A1 INHIBITOR OF HEME DEGRADATION FOR USE TO IMPROVE ANTIBIOTIC TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTION HMOX1, HMOX2, PPOX CYP19A1 3664/4885CYP1A2 614/4885CYP2D6 1064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.